PVP Ventures Limited (PVP)
₹39.72 -4.43% last close, 23 Oct
Snapshot
PVP Ventures Limited closed at ₹39.72 on 23 Oct 2026, 11.7% above its 200-day average, with an RSI(14) of 31.2. On the daily chart it is in a strong downtrend, with a technical score of 24/100 (strong bearish). In the quarter ended June 2026, revenue grew 165.2% and net profit grew 10157.4% from a year earlier. Data as of 23 Oct 2026.
Price
- Price
- ₹39.72
- Day change
- -4.43%
- Market Cap
- ₹1,034 Cr
- 52-week range
- ₹23.00 – ₹72.04
- From 52-week high
- -44.86%
Financials23 Oct 2026
- P/E
- n/m
- P/B
- 4.74
- ROE
- 0.6%
- ROCE
- 6.2%
- Debt to Equity
- 1.17
- OPM
- 22.7%
- YoY qtr sales growth
- 165.2%
- YoY qtr profit growth
- 10,157.4%
- Dividend Yield
- 0.00%
Latest quarter Jun 2026 · Consolidated
Technicals23 Oct 2026
- Trend
- Strong Downtrend
- Technical score
- 24/100 · Strong bearish
- MACD
- Bearish
- RSI (14)
- 31.20
- ADX (14)
- 29.97
- SuperTrend
- Bearish
- vs 20-day SMA
- -20.93%
- vs 50-day SMA
- -26.03%
- vs 200-day SMA
- +11.72%
- RS rating
- 91.00
- Nearest support
- ₹39.12
- Nearest resistance
- ₹45.56
Exchange activity23 Oct 2026
- Delivery
- 61.3% vs 56.71% average
- Volume vs its average
- 0.9×
- Price band
- Lower band, 23 Oct
Events
- Latest results
- Q1 FY27, filed 15 Aug 2026
Exchange data. Each figure as its own page shows it; the dates are the data's. Information only, not investment advice.
📈 Share price & events
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, PVP Ventures' revenue was ₹45.6 Cr (+165.2% year on year, +10.1% on the previous quarter), and net profit ₹11.1 Cr (against a loss a year earlier); the operating margin was 29.1%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹45.6 | +165.2% | +10.1% |
| Operating profit | ₹13.3 | +163.9% | +84.2% |
| Net profit | ₹11.1 | from loss | from loss |
| EPS (₹) | 0.46 | — | from loss |
| Operating margin | 29.1% | — | — |
PVP delivery percentage
NSE end-of-day data for
On Fri, 23 Oct 2026, 61.3% of the PVP shares traded on NSE were taken to delivery, against the stock's own 20-session average of 56.71%. That is close to its usual level. It closed at its lower price band (circuit) on 23 Oct, one of 13 band closes in about the last 20 sessions.
Delivery in the last 5 sessions: 67.0% · 39.6% · 54.6% · 46.8% · 61.3%
A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed
📢 Recent Corporate Announcements
Evervie Health Limited (formerly PVP Ventures Limited) has signed a Letter of Intent (LOI) with Sweden-based Elekta Solutions AB to procure 10 HARMONY linear accelerator (LINAC) oncology systems. The deal value is estimated between $11 million and $15 million USD (approx. ₹90-125 Cr), which is substantial compared to the company's TTM revenue of ₹118 Cr and market cap of ₹277 Cr. The machines will be operated via its subsidiary, Optimus Oncology Private Limited, with phased deliveries expected through October 2028. The LOI is non-binding and subject to final definitive agreements, financing arrangements, and regulatory approvals.
- LOI signed for procurement of 10 HARMONY linear accelerator (LINAC) systems from Elekta Solutions AB
- Estimated commercial consideration of $11 million to $15 million USD, payable in SEK
- Procurement value represents a significant capex commitment relative to TTM revenue of ₹118 Cr
- Phased delivery planned in two tranches of 5 units each, targeted for completion by October 2028
- Equipment to be operated by subsidiary Optimus Oncology Private Limited
Evervie Health Limited (formerly PVP Ventures Limited) submitted a routine compliance disclosure under SEBI Master Circular guidelines regarding its outstanding Non-Convertible Debentures (NCDs). The company confirmed two active NCD tranches totaling ₹150 Cr (₹95 Cr under ISIN INE362A07054 and ₹55 Cr under ISIN INE362A07047). Both series carry a high coupon rate of 18% per annum payable quarterly, were issued on April 9, 2025, and mature on March 31, 2029.
- Submitted regulatory disclosure for ₹150 Cr total outstanding Non-Convertible Debentures across two ISINs
- Tranche 1 (ISIN INE362A07054): ₹95 Cr issued and ₹95 Cr outstanding at an 18% coupon rate
- Tranche 2 (ISIN INE362A07047): ₹55 Cr issued and ₹55 Cr outstanding at an 18% coupon rate
- Both instruments carry quarterly payment frequency and mature on March 31, 2029
Evervie Health Limited (formerly known as PVP Ventures Limited) has submitted its compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026. The confirmation from Registrar and Share Transfer Agent KFin Technologies Limited verifies that securities received for dematerialisation were processed and confirmed within 15 days. Security certificates received were duly mutilated, cancelled, and the depository names substituted in the register of members. This is a mandatory, recurring quarterly compliance filing with no impact on business operations or financials.
- Compliance certificate submitted under Regulation 74(5) for the quarter ended 30 September 2026
- Confirmation received from Registrar and Share Transfer Agent KFin Technologies Limited dated 09 October 2026
- Securities certificates mutilated and cancelled, with depository names updated within 15 days
Evervie Health Limited (formerly PVP Ventures Limited) has paid ₹13.46 Cr in advance on 08 October 2026 towards scheduled interest on its Non-Convertible Debentures. The payment covers two upcoming quarters: contractual due dates of 31 December 2026 and 31 March 2027. The interest relates to Series A (₹95 Cr issue size) and Series B (₹55 Cr issue size) debentures, totaling ₹150 Cr in aggregate principal. This prepayment indicates immediate liquidity headroom to service its high-coupon debt obligations.
- Prepaid total interest of ₹13.46 Cr in advance on 08 October 2026
- Covers two future quarterly cycles due on 31 December 2026 and 31 March 2027
- ₹8.53 Cr paid on Series A debentures (issue size ₹95 Cr)
- ₹4.94 Cr paid on Series B debentures (issue size ₹55 Cr)
PVP Ventures completed quarterly interest payments totaling approximately Rs 1.04 Cr on its Non-Convertible Debentures (NCDs) aggregating Rs 150 Cr across two ISINs. The payments of Rs 65.68 lakh (on Rs 95 Cr issue) and Rs 38.02 lakh (on Rs 55 Cr issue) were due on September 30, 2026, but were paid on October 3, 2026. The company stated that the three-day delay was due to a technical issue. Total debt stands at Rs 207 Cr against a net worth of Rs 214 Cr.
- Paid quarterly interest of Rs 65,67,580 on Rs 95,00,00,000 NCD issue (INE362A07054)
- Paid quarterly interest of Rs 38,02,283 on Rs 55,00,00,000 NCD issue (INE362A07047)
- Interest due date was 30th September, 2026; actual payment made on 03rd October, 2026
- Company cited 'Due to technical issue' as the reason for the 3-day payment delay
PVP Ventures announced the resignation/cessation of both Dr. Ellen Jane Feehan (Executive Director & CEO) and Dr. Neeraja Nagarajan (Executive Director & COO), effective September 24, 2026. Dr. Feehan cited unavoidable personal and health reasons, terminating her Executive Employment Agreement (signed July 6, 2026) prior to her scheduled joining date of October 1, 2026. Dr. Nagarajan resigned following the non-alignment of Dr. Feehan, citing leadership differentials and personal commitments in the United States. This leaves the top executive management vacant just as the company attempts to pivot into healthcare operations.
- Resignation of both Executive Director & CEO (Dr. Ellen Jane Feehan) and Executive Director & COO (Dr. Neeraja Nagarajan) effective September 24, 2026.
- Dr. Feehan terminated her Executive Employment Agreement signed on July 6, 2026 ab initio ahead of the October 1, 2026 start date.
- Dr. Nagarajan resigned due to the departure of Dr. Feehan, leadership structure differences, and US domicile requirements.
- Cessations impact PVP Ventures' planned leadership team for its healthcare pivot (Evervie Health).
PVP Ventures Limited has announced the resignation of Dr. Neeraja Nagarajan from her position as Executive Director & Chief Operating Officer (COO), effective September 24, 2026. The resignation was tendered citing personal reasons. PVP Ventures operates in residential real estate and healthcare services with a market cap of ₹395 Cr and TTM revenue of ₹118 Cr.
- Dr. Neeraja Nagarajan resigned as Executive Director & COO
- Cessation date effective September 24, 2026
- Reason stated is personal reasons
- Company indicated disclosures under Clause 7(C) will follow in due course
PVP Ventures Limited has announced September 23, 2026, as the record date for scheduled interest payments on its Non-Convertible Debentures (ISINs: INE362A07054 and INE362A07047). The corresponding interest payout is scheduled to be completed on October 8, 2026. This is a routine administrative compliance disclosure under Regulation 60(2) of SEBI LODR Regulations. Company filings indicate debt servicing for these high-coupon (18%) NCDs remains a critical recurring cash outflow against its Rs 207 Cr debt load.
- Record date fixed as Wednesday, September 23, 2026
- Scheduled interest payment date set for Thursday, October 8, 2026
- Applies to two NCD ISINs: INE362A07054 and INE362A07047
- Company carries total debt of Rs 207 Cr with notable 18% NCD obligations
PVP Ventures Limited conducted its 35th Annual General Meeting (AGM) on September 7, 2026, via video conferencing. The company announced that all resolutions outlined in the AGM notice were approved by shareholders with the requisite majority. The scrutinizer's report detailing the voting results has been submitted to the exchanges in compliance with Regulation 44 of SEBI LODR. The filing represents a regular statutory compliance disclosure with no operational or financial disruptions.
- 35th Annual General Meeting held on September 7, 2026, at 10:00 AM IST
- Meeting conducted virtually through Video Conferencing / Other Audio-Visual Means
- All resolutions approved by shareholders with requisite majority as per Scrutinizer's report
PVP Ventures Limited conducted its 35th Annual General Meeting on September 07, 2026, via Video Conferencing. A total of 59 shareholders attended the meeting, satisfying the quorum requirements, and 10 registered speaker shareholders raised queries. The company confirmed that final consolidated remote and AGM e-voting results will be declared and filed within two working days.
- 35th Annual General Meeting convened on September 07, 2026, from 10:00 A.M. to 10:50 A.M. IST
- Quorum was met with 59 shareholders attending via Video Conferencing
- Queries from 10 registered speaker shareholders were addressed by the Chairman
- Consolidated voting results to be declared and submitted to stock exchanges within two working days
PVP Ventures Limited announced that its Board of Directors approved the resignation of Mr. B Vignesh Ram from the position of Company Secretary and Compliance Officer at its meeting on September 7, 2026. The resignation is due to personal reasons and will take effect from September 11, 2026. The company will need to appoint a successor to manage corporate secretarial compliance under SEBI LODR norms.
- Board approved the resignation of Mr. B Vignesh Ram on September 7, 2026
- Resignation takes effect from September 11, 2026
- Reason cited for departure is personal reasons
- Company to initiate appointment of a new Company Secretary & Compliance Officer
PVP Ventures Limited announced the appointment of Mr. Vinay Paruchuru as its new Company Secretary and Compliance Officer, effective September 14, 2026. This follows the resignation of Mr. B Vignesh Ram from the position, which takes effect on September 11, 2026. Mr. Paruchuru brings over 15 years of experience in corporate secretarial and listing compliance functions, having previously served with Pokarna Limited and the Kapil Group.
- Appointment of Mr. Vinay Paruchuru as Company Secretary & Compliance Officer effective September 14, 2026
- Resignation of Mr. B Vignesh Ram as Company Secretary & Compliance Officer effective September 11, 2026
- Incoming CS brings over 15 years of corporate secretarial and governance experience
- Board meeting approving the management change concluded at 11:30 A.M. on September 07, 2026
Acuité Ratings & Research has assigned an investment-grade rating of 'ACUITE BBB- | Stable' to PVP Ventures Limited's Non-Convertible Debentures (NCDs) aggregating to ₹150.00 Cr. The rated facilities include two long-term tranches of ₹95.00 Cr (ISIN INE362A07054) and ₹55.00 Cr (ISIN INE362A07047). The ₹150.00 Cr rated instruments account for roughly 72.5% of the company's total debt of ₹207 Cr. This rating establishes formal credit benchmarks for the company's long-term borrowing facilities.
- Acuité assigned 'ACUITE BBB-
- Stable' rating to ₹150.00 Cr of long-term NCDs on September 02, 2026
- NCD Tranche 1 (ISIN INE362A07054) covers ₹95.00 Cr in long-term debentures
- NCD Tranche 2 (ISIN INE362A07047) covers ₹55.00 Cr in long-term debentures
- Rated debt of ₹150.00 Cr represents ~72.5% of PVP's total debt (₹207 Cr) and ~70% of net worth (₹214 Cr)
PVP Ventures has issued a corrigendum to Item No. 10 of its 35th AGM notice scheduled for September 7, 2026. The revised special resolution seeks shareholder approval for the re-appointment of Mr. Prasad V. Potluri as Chairman & Managing Director for a 5-year term ending in 2031. It also seeks approval for managerial remuneration of ₹5.00 crore for FY 2026-27 even in the absence or inadequacy of profits. Additionally, the resolution approves payment of fees to the CMD at 2% p.a. on collateral securities and 1% p.a. on personal guarantees provided for company borrowings.
- Re-appointment of Mr. Prasad V. Potluri as CMD for a 5-year term from 35th AGM till AGM 2031
- Approval sought for ₹5.00 crore managerial remuneration for FY 2026-27 under Schedule V
- Proposed fee of 2% p.a. on value of collateral securities provided by CMD for company credit facilities
- Proposed fee of 1% p.a. on value of personal guarantees extended by CMD for borrowings
- AGM scheduled to be held on 07th September 2026
PVP Ventures Limited has issued an addendum to its 35th Annual General Meeting (AGM) notice scheduled for September 7, 2026. The addendum encloses a compliance certificate issued by a Practicing Chartered Accountant under Regulation 45(3) of SEBI LODR Regulations. This certificate pertains to Item No. 5 of the AGM Notice regarding the proposed change of name of the company. All other contents of the Annual Report for FY 2025-26 remain unchanged.
- Submitted addendum to the Notice of the 35th Annual General Meeting on August 20, 2026
- AGM scheduled for Monday, September 7, 2026 at 10:00 AM IST via VC/OAVM
- Enclosed Practicing Chartered Accountant compliance certificate under Regulation 45(3) of SEBI LODR
- Certificate pertains specifically to Item No. 5 regarding proposed change of company name
Company profilewritten 14 Dec 2025
Financial Performance
Revenue Growth by Segment
Consolidated revenue for the six months ended September 30, 2025, was INR 20.95 Cr. Real estate revenue is driven by Project Rainbow (INR 107 Cr total potential) and Project Mercury. Healthcare revenue is contributed by Humain Healthtech (HHT), which saw a 56% increase in investment value to INR 40.62 Cr in FY25.
Geographic Revenue Split
100% of revenue is derived from India, primarily concentrated in Chennai, Tamil Nadu, where the core 70-acre Binny Mill land parcel and residential projects are located.
Profitability Margins
Net profit for the six months ended September 30, 2025, was INR 0.48 Cr, representing a net margin of approximately 2.3%. Profitability is impacted by a recognized impairment loss of INR 6.70 Cr on healthcare investments in FY25.
EBITDA Margin
Operating profitability is expected to steadily improve from the current low single-digit levels as the company scales its healthcare services and completes the 283-292 unsold units in Project Rainbow.
Capital Expenditure
Property, Plant and Equipment (PPE) increased by 268% from INR 0.60 Cr in FY24 to INR 2.21 Cr in FY25, reflecting investments in healthcare infrastructure and project development.
Credit Rating & Borrowing
The company has a 'Stable' outlook for its long-term ratings. Borrowing costs are high, with a planned INR 150 Cr NCD issue carrying an 18% coupon rate, reflecting the project-specific risk profile.
Operational Drivers
Raw Materials
Land (70-acre legacy parcel), Construction Services (Joint Development Agreement), and Medical Equipment (for healthcare diagnostic services).
Import Sources
Primarily sourced locally within Tamil Nadu, India, for construction and land development; medical equipment is sourced from domestic and international technology providers.
Key Suppliers
Casa Builders Private Limited (Joint Development Partner for real estate projects) and PV Potluri Ventures Private Limited (Related party for healthcare asset acquisition).
Capacity Expansion
Project Rainbow has 283-292 unsold units as of May 2025. Project Mercury is in a nascent stage with a planned completion timeline of November 2029. Healthcare capacity expanded through the 100% acquisition of Humain Healthtech.
Raw Material Costs
Land represents the primary asset value, with intercompany loans of INR 125 Cr related to project land acquisition for Project Mercury. Construction costs are shared under a JDA with Casa Builders.
Manufacturing Efficiency
The company is expected to maintain an average cash coverage ratio of 1.41x for the period FY 2026-2030 to service its 18% debt obligations.
Logistics & Distribution
Distribution is managed through the JDA partner, Casa Builders, who is responsible for selling the inventory position in the competitive Chennai market.
Strategic Growth
Growth Strategy
Growth will be achieved through the launch of Project Mercury in Q3FY26, the liquidation of INR 107 Cr in cash flow potential from Project Rainbow, and the scaling of healthcare services via Humain Healthtech and Apta Medical Imaging.
Products & Services
Residential apartments (Project Rainbow and Project Mercury), healthcare diagnostic services, and medical imaging services.
Brand Portfolio
PVP, Humain Health, Apta Medical Imaging.
New Products/Services
Expansion into green-rated properties and digitally integrated real estate developments to meet shifting Indian market benchmarks.
Market Expansion
Strategic pivot from media and entertainment into healthcare services and large-scale residential real estate in the Chennai metropolitan region.
Strategic Alliances
Joint Development Agreement (JDA) with Casa Builders Private Limited for the execution and marketing of residential projects.
External Factors
Industry Trends
The Indian real estate industry is evolving toward sustainability, with a rise in green-rated properties and digitally integrated developments reshaping the landscape.
Competitive Landscape
Faces intense competition from other developers in the close vicinity of its Chennai projects, exacerbated by its dependence on a JDA partner for sales.
Competitive Moat
The primary moat is the legacy 70-acre land parcel in the heart of Chennai (Binny Mill), which provides a low-cost, high-value asset base that is difficult for competitors to replicate in urban centers.
Macro Economic Sensitivity
Highly sensitive to interest rate cycles in India, as the 18% coupon on its own debt and the mortgage rates for its retail customers directly impact project viability and sales velocity.
Consumer Behavior
Shift toward 'future-ready' real estate with integrated technology and sustainability features is driving product design for new launches.
Geopolitical Risks
Low, as operations are entirely domestic; however, regulatory changes in RERA or the Companies Act (Section 135/198) impact compliance costs.
Regulatory & Governance
Industry Regulations
Strict adherence to RERA timelines is required, with Project Rainbow due by October 2025 and Project Mercury by November 2029 to avoid regulatory penalties and marketing risks.
Environmental Compliance
Increasing focus on green-rated property benchmarks to comply with evolving sustainability standards in the Indian real estate sector.
Taxation Policy Impact
The company maintains a Deferred Tax Asset (net) of INR 6.23 Cr as of March 31, 2025.
Legal Contingencies
Significant governance risk involving INR 391.15 Cr in unsecured loans to related parties (PVP Global and PVP Media) flagged as prejudicial to company interests. Additionally, INR 28 Cr is outstanding from Picturehouse Media Limited, which has a negative net worth.
Risk Analysis
Key Uncertainties
Project execution risk for Project Mercury (nascent stage) and the recoverability of INR 391.15 Cr in related-party loans could impact the financial risk profile by more than 50% of the asset base.
Geographic Concentration Risk
100% of real estate assets and projects are located in Chennai, exposing the company to localized economic downturns or regulatory shifts in Tamil Nadu.
Third Party Dependencies
Critical dependency on Casa Builders Private Limited for the successful sale of the 283-292 unsold units in Project Rainbow.
Technology Obsolescence Risk
Risk of falling behind in the 'digitally integrated development' trend if new projects do not incorporate modern smart-home and sustainable technologies.
Credit & Counterparty Risk
High exposure to Picturehouse Media Limited (INR 28 Cr) and other related parties, where negative net worth and continuing losses pose significant recovery challenges.
